Literature DB >> 30123540

PD-L1 immunohistochemistry in patients with non-small cell lung cancer.

Takanobu Jotatsu1, Keishi Oda1, Kazuhiro Yatera1.   

Abstract

Entities:  

Year:  2018        PMID： 30123540      PMCID： PMC6072943          DOI： 10.21037/jtd.2018.06.30

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

2.  Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.

Authors:  J Adam; N Le Stang; I Rouquette; A Cazes; C Badoual; H Pinot-Roussel; L Tixier; C Danel; F Damiola; D Damotte; F Penault-Llorca; S Lantuéjoul
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

3.  Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.

Authors:  Daichi Fujimoto; Yuki Sato; Keiichiro Uehara; Kaori Ishida; Junya Fukuoka; Takeshi Morimoto; Hayato Kawachi; Ryobu Mori; Munehiro Ito; Shunsuke Teraoka; Kazuma Nagata; Atsushi Nakagawa; Kojiro Otsuka; Yukihiro Imai; Keisuke Tomii
Journal:  J Thorac Oncol       Date:  2017-12-09       Impact factor: 15.609

4.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

5.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.

Authors:  Tzahi Neuman; Michal London; Juliane Kania-Almog; Anna Litvin; Yaniv Zohar; Ludmila Fridel; Judith Sandbank; Iris Barshak; Gilad W Vainer
Journal:  J Thorac Oncol       Date:  2016-09-21       Impact factor: 15.609

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Authors:  Andreas H Scheel; Manfred Dietel; Lukas C Heukamp; Korinna Jöhrens; Thomas Kirchner; Simone Reu; Josef Rüschoff; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Arne Warth; Wilko Weichert; Rieke N Fischer; Jürgen Wolf; Reinhard Buettner
Journal:  Mod Pathol       Date:  2016-07-08       Impact factor: 7.842

10.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Authors:  David L Rimm; Gang Han; Janis M Taube; Eunhee S Yi; Julia A Bridge; Douglas B Flieder; Robert Homer; William W West; Hong Wu; Anja C Roden; Junya Fujimoto; Hui Yu; Robert Anders; Ashley Kowalewski; Christopher Rivard; Jamaal Rehman; Cory Batenchuk; Virginia Burns; Fred R Hirsch; Ignacio I Wistuba
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777
View more
  5 in total

1.  Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.

Authors:  Nick Freemantle; Yingxin Xu; Florence R Wilson; Patricia Guyot; Chieh-I Chen; Sam Keeping; Gerasimos Konidaris; Keith Chan; Andreas Kuznik; Kokuvi Atsou; Emily Glowienka; Jean-Francois Pouliot; Giuseppe Gullo; Petra Rietschel
Journal:  Ther Adv Med Oncol       Date:  2022-06-16       Impact factor: 5.485

2.  An immunogold single extracellular vesicular RNA and protein (Au SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients.

Authors:  Luong T H Nguyen; Jingjing Zhang; Xilal Y Rima; Xinyu Wang; Kwang Joo Kwak; Tamio Okimoto; Joseph Amann; Min Jin Yoon; Takehito Shukuya; Chi-Ling Chiang; Nicole Walters; Yifan Ma; Donald Belcher; Hong Li; Andre F Palmer; David P Carbone; L James Lee; Eduardo Reátegui
Journal:  J Extracell Vesicles       Date:  2022-09

3.  Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.

Authors:  Bregje M Koomen; Jose van der Starre-Gaal; Judith M Vonk; Jan H von der Thüsen; Jacqueline J C van der Meij; Kim Monkhorst; Stefan M Willems; Wim Timens; Nils A 't Hart
Journal:  Cancer Cytopathol       Date:  2020-10-27       Impact factor: 5.284

4.  Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.

Authors:  Jianjun Jin; Jiming Si; Yuanhua Liu; Huanqin Wang; Ran Ni; Jing Wang
Journal:  Respir Res       Date:  2018-10-05

5.  Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications.

Authors:  Kyoungmin Lee; Yoon J Choi; Jung S Kim; Dae S Kim; Sung Y Lee; Bong K Shin; Eun J Kang
Journal:  Thorac Cancer       Date:  2021-06-13       Impact factor: 3.500
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.